Abstract
Metabolism of tumor tissue differs from the normal one by the intensity of protein synthesis and glycolysis. The dimeric pyruvate kinase (PKM2) is a specific enzyme for tumor glycolysis. The aim of this study was to determine the relationship between the activity of PKM2 and the type and stage of non-small cell lung cancer (NSCLC). A second objective was to compare the expression of PKM2 with disease progression and prognosis. We studied 65 patients divided into two groups: 45 patients with lung cancer and 20 non-cancer healthy subjects taken as control. The serum activity of PKM2 was assessed spectrophotometrically. We found that PKM2 activity was greater, on average, by 136 % for adenocarcinoma and for 126 % for squamous cell carcinoma compared with that present in control subjects. The higher PKM2 activity was associated only with Stage III of cancer (p < 0.001). Sensitivity of PKM2 as a cancer marker was 79 % for adenocarcinoma and 81 % for squamous cell carcinoma and specificity was 50 % for both cancer types. We conclude that PKM2 activity is higher in patients with NSCLC than in healthy subjects. The level of PKM2 activity is associated with advanced stage of cancer. Nonetheless, low specificity of PKM2 assessment makes it of limited utility in NSCLC diagnosis or evaluation of cancer progression.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdullah M, Rani AA, Simadibrata M, Fauzi A, Syam AF (2012) The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening. Acta Med Indones 44(2):94–99
Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC (2008) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452(7184):181–186
Demır AS, Erdenen F, Müderrısoğlu C, Toros AB, Bektaş H, Gelışgen R, Tabak Ö, Altunoğlu E, Uzun H, Erdem Huq GE, Aral H (2013) Diagnostic and prognostic value of tumor M2-pyruvate kinase levels in patients with colorectal cancer. Turk J Gastroenterol 24(1):36–42
Ervens J, Fuchs H, Niemann VT, Hoffmeister B (2008) Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer. J Craniomaxillofac Surg 36(2):89–94
Garon EB, Christofk HR, Hosmer W et al (2014) Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 140(3):443–452
Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK (2007) Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer - Evidence for a novel biological marker of adverse prognosis. Pancreas 34(3):318–324
Hardt PD, Ewald N (2008) Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy. Expert Rev Mol Diagn 8(5):579–585
Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU (2003) Measurement of fecal pyruvate kinase type M2 (Tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 23(2A):851–853
Kobierzycki C, Pula B, Werynska B, Piotrowska A, Muszczynska-Bernhard B, Dziegiel P, Rakus D (2014) The Lack of evidence for correlation of pyruvate kinase M2 expression with tumor grade in non-small cell lung cancer. Anticancer Res 34(7):3811–3817
Kumar Y, Gurusamy K, Pamecha V, Davidson BR (2007) Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer; a meta-analysis. Pancreas 35(2):114–119
Kumar Y, Pinedo IR, Tapuria N, Zabron A, Davidson BR (2008) A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases. Eur J Gastroenterol Hepatol 20(10):1006–1011
Li R, Liu J, Xue H, Huang G (2012) Diagnostic value of fecal tumor M2-pyruvate kinase on colorectal cancer: a meta-analysis. Int J Cancer 131(8):1837–1845
Meng MB, Wang HH, Guo WH, Wu ZQ, Zeng XL, Zaorsky NG, Shi HS, Qian D, Niu ZM, Jiang B, Zhao LJ, Yuan ZY, Wang P (2015) Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell lung cancer cells in vitro and in vivo. Cancer Lett 356(2):985–993
Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek EJR (2012) The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol 4(4):128–134
Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111(6):1710–1717
Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, Tsakalaki E, Voutsina A, Koutsopoulos A, Mavroudis D, Georgoulias V, Souglakos J (2014) PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. Br J Cancer 111(9):1757–1764
Peng XC, Gong FM, Zhao YW, Zhou LX, Xie YW, Liao HL, Lin HJ, Li ZY, Tang MH, Tong AP (2011) Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma. PLoS ONE 6(11), e27309. doi:10.1371/journal.pone.0027309
Roudier E, Perrin A (2009) Considering the role of pyruvate in tumor cells during hypoxia. Biochim Biophys Acta 1796(2):55–62
Schneider J, Schulze G (2003) Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19–9 and CA 72–4 in the diagnosis of gastrointestinal cancer. Anticancer Res 23(6D):5089–5093
Schulze G (2000) The tumor marker tumor M2-PK: An application in the diagnosis of gastrointestinal cancer. Anticancer Res 20(6D):4961–4964
Voorzanger-Rousselot N, Garnero P (2007) Biochemical markers in oncology. Part I: Molecular basis. Part II: Clinical uses. Cancer Treat Rev 33(3):230–283
Warburg O (1956) Origin of cancer cells. Science 123(3191):309–314
Zhang B, Chen JY, Chen DD, Wang GB, Shen P (2004) Tumor type M-2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol 10(11):1643–1646
Acknowledgements
This work was supported by the statutory budget of Wroclaw Medical University in Poland.
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Rzechonek, A., Kaminska, A., Mamczur, P., Drapiewski, A., Budzynski, W. (2016). Limited Clinical Significance of Dimeric Form of Pyruvate Kinase as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Cancer. In: Pokorski, M. (eds) Pathobiology of Pulmonary Disorders. Advances in Experimental Medicine and Biology(), vol 955. Springer, Cham. https://doi.org/10.1007/5584_2016_92
Download citation
DOI: https://doi.org/10.1007/5584_2016_92
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-49294-0
Online ISBN: 978-3-319-49295-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)